PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
|Articles|July 24, 2012
Deloitte: One in 10 U.S. Employers to Drop Health Coverage
Advertisement
Around one in 10 employers in the U.S. plans to drop health coverage for workers in the next few years as the bulk of the federal health-care law begins, and more indicated they may do so over time, according to a study to be released Tuesday by consulting company Deloitte.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.
In 299 patients, more involved compartments were linked to higher complication risk after one-stage resection; 14.4% had documented recurrence.
A cranberry supplement was tied to greater OAB symptom score reductions than placebo in a 25-woman pilot trial, but urobiome findings were unconfirmed.
A runner's death at the NYC marathon highlights how heat, dehydration, illness, drugs, and genetics can raise exertional rhabdomyolysis risk.
ALLEGRO extension news shows Litfulo (ritlecitinib) delivers durable hair regrowth in severe alopecia areata after 3 years.
The GOLD International COPD Conference will cover underdiagnosis, exacerbations, mucus, biologics, and a preview of the 2027 GOLD Report.
People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Policy, AI, and High-Cost Therapies Shape AMCP Nexus 2026 Discussions
3
Ritlecitinib Sustains Hair Regrowth in Alopecia Areata Through 3 Years
4
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
5